Glucotrack, Inc. (Nasdaq: GCTK) announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent application titled "Methods and Systems for Continuously Monitoring the Glucose Level of a Patient," covering its implantable continuous blood glucose monitoring platform.

The allowed claims cover implantable glucose monitoring systems that use an intravascular sensing lead coupled to an electronics assembly, including electrode configurations, lead-based sensing structures, and methods for continuous glucose measurement within the vasculature.

The new allowance adds to three CBGM patents the USPTO issued in late 2025 — US 12,453,494; US 12,458,257; and US 12,458,258 — further extending intellectual property protection across the company's sensor architecture.

Paul V. Goode, PhD, President and Chief Executive Officer of Glucotrack, said: "This allowed application strengthens the protection around key elements of our CBGM, including novel sensor architectures designed to support long-term intravascular glucose monitoring. Continuing to build our intellectual property is fundamental to our strategy as we advance the fully implantable system through clinical testing and toward commercialization."

Glucotrack's CBGM is described as a long-term implantable system with no wearable component, designed for up to three years of continuous blood glucose monitoring. The device measures glucose directly from blood rather than interstitial fluid. It remains an investigational device limited by federal law to investigational use.